A once-weekly injectable GIP/GLP-1 dual agonist conferred up to 22.5% weight loss at 48 weeks for adults with overweight or ...

Medically reviewed by Roxana Ehsani, RD Key Takeaways BMI is a common method to define overweight and obesity.Obesity is a ...

Overweight has developed into a global health crisis – with dramatic consequences also in Austria. Experts are sounding the ...

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from ...

New research on children diagnosed with acute lymphoblastic leukemia (ALL) shows that the longer a patient's body mass index (BMI) falls within the overweight/obese category during treatment, the ...

New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that the proportion of adolescents living with overweight or obesity in England has ...

By Priyanjana Pramanik, MSc. A randomized Canadian trial shows that three daily servings of full-fat dairy can fit safely into a healthy eating pattern without harming weight or cardiometabolic ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. | GLP-1 ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or obesity who do not have diabetes, according to new ...

GLP-1RAs were linked to fewer asthma exacerbations and emergency visits in teens with obesity, suggesting potential ...

Compared with placebo, tirzepatide was associated with a slower decline in eGFR among patients with prediabetes and overweight or obesity. Tirzepatide improves kidney outcomes among patients with ...